ATAD1 and parasitic infectious disease: Across all immunized volunteers in this dose de-escalation trial (Figure 1), magnitudes of CSP and MSP-1 antibody responses after the third immunization correlated with the cumulative level of blood-stage parasitemia to which volunteers were exposed over the course of the 3 immunizations (Figure 4E).